Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients

Elisa Ferretti, Stefan Hohaus, Arianna Di Napoli, Beatrice Belmonte, Annarosa Cuccaro, Elisa Cupelli, Eugenio Galli, Vittoria Rufini, Gino Tripodi, Giulio Fraternali-Orcioni, Vito Pistoia, Anna Corcione

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes expressed intracytoplasmic and surface IL-31/TSLP, and their receptors. A subgroup of patients showing at diagnosis elevated IL-31 and TSLP plasma levels had an International Prognostic Score>2, indicative of high risk of relapse, and a subsequent positive interim PET-scan, indicative of insufficient response to chemotherapy. No correlation was found between IL-31/TSLP plasma levels and overall or event-free survival. In conclusion, IL-31/TSLP and their receptors are expressed in HL cells and in immune cells infiltrating affected lymph nodes, where both cytokines may contribute to local immune suppression. The clinical impact of IL-31 and TSLP plasma levels has to be further defined in larger patient cohorts.

Original languageEnglish
Pages (from-to)85263-85275
Number of pages13
JournalOncotarget
Volume8
Issue number49
DOIs
Publication statusPublished - Oct 17 2017

Fingerprint

Interleukins
Hodgkin Disease
Lymph Nodes
Cytokines
thymic stromal lymphopoietin
Chemokines
Positron-Emission Tomography
Disease-Free Survival
Neoplasms
Flow Cytometry
B-Lymphocytes
Enzyme-Linked Immunosorbent Assay
Recurrence
Drug Therapy

Keywords

  • Journal Article

Cite this

Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. / Ferretti, Elisa; Hohaus, Stefan; Di Napoli, Arianna; Belmonte, Beatrice; Cuccaro, Annarosa; Cupelli, Elisa; Galli, Eugenio; Rufini, Vittoria; Tripodi, Gino; Fraternali-Orcioni, Giulio; Pistoia, Vito; Corcione, Anna.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 85263-85275.

Research output: Contribution to journalArticle

Ferretti, E, Hohaus, S, Di Napoli, A, Belmonte, B, Cuccaro, A, Cupelli, E, Galli, E, Rufini, V, Tripodi, G, Fraternali-Orcioni, G, Pistoia, V & Corcione, A 2017, 'Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients', Oncotarget, vol. 8, no. 49, pp. 85263-85275. https://doi.org/10.18632/oncotarget.19665
Ferretti E, Hohaus S, Di Napoli A, Belmonte B, Cuccaro A, Cupelli E et al. Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. Oncotarget. 2017 Oct 17;8(49):85263-85275. https://doi.org/10.18632/oncotarget.19665
Ferretti, Elisa ; Hohaus, Stefan ; Di Napoli, Arianna ; Belmonte, Beatrice ; Cuccaro, Annarosa ; Cupelli, Elisa ; Galli, Eugenio ; Rufini, Vittoria ; Tripodi, Gino ; Fraternali-Orcioni, Giulio ; Pistoia, Vito ; Corcione, Anna. / Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. In: Oncotarget. 2017 ; Vol. 8, No. 49. pp. 85263-85275.
@article{a49a851bfd924829bc24eac596c5f7fd,
title = "Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients",
abstract = "Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes expressed intracytoplasmic and surface IL-31/TSLP, and their receptors. A subgroup of patients showing at diagnosis elevated IL-31 and TSLP plasma levels had an International Prognostic Score>2, indicative of high risk of relapse, and a subsequent positive interim PET-scan, indicative of insufficient response to chemotherapy. No correlation was found between IL-31/TSLP plasma levels and overall or event-free survival. In conclusion, IL-31/TSLP and their receptors are expressed in HL cells and in immune cells infiltrating affected lymph nodes, where both cytokines may contribute to local immune suppression. The clinical impact of IL-31 and TSLP plasma levels has to be further defined in larger patient cohorts.",
keywords = "Journal Article",
author = "Elisa Ferretti and Stefan Hohaus and {Di Napoli}, Arianna and Beatrice Belmonte and Annarosa Cuccaro and Elisa Cupelli and Eugenio Galli and Vittoria Rufini and Gino Tripodi and Giulio Fraternali-Orcioni and Vito Pistoia and Anna Corcione",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.19665",
language = "English",
volume = "8",
pages = "85263--85275",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "49",

}

TY - JOUR

T1 - Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients

AU - Ferretti, Elisa

AU - Hohaus, Stefan

AU - Di Napoli, Arianna

AU - Belmonte, Beatrice

AU - Cuccaro, Annarosa

AU - Cupelli, Elisa

AU - Galli, Eugenio

AU - Rufini, Vittoria

AU - Tripodi, Gino

AU - Fraternali-Orcioni, Giulio

AU - Pistoia, Vito

AU - Corcione, Anna

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes expressed intracytoplasmic and surface IL-31/TSLP, and their receptors. A subgroup of patients showing at diagnosis elevated IL-31 and TSLP plasma levels had an International Prognostic Score>2, indicative of high risk of relapse, and a subsequent positive interim PET-scan, indicative of insufficient response to chemotherapy. No correlation was found between IL-31/TSLP plasma levels and overall or event-free survival. In conclusion, IL-31/TSLP and their receptors are expressed in HL cells and in immune cells infiltrating affected lymph nodes, where both cytokines may contribute to local immune suppression. The clinical impact of IL-31 and TSLP plasma levels has to be further defined in larger patient cohorts.

AB - Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes expressed intracytoplasmic and surface IL-31/TSLP, and their receptors. A subgroup of patients showing at diagnosis elevated IL-31 and TSLP plasma levels had an International Prognostic Score>2, indicative of high risk of relapse, and a subsequent positive interim PET-scan, indicative of insufficient response to chemotherapy. No correlation was found between IL-31/TSLP plasma levels and overall or event-free survival. In conclusion, IL-31/TSLP and their receptors are expressed in HL cells and in immune cells infiltrating affected lymph nodes, where both cytokines may contribute to local immune suppression. The clinical impact of IL-31 and TSLP plasma levels has to be further defined in larger patient cohorts.

KW - Journal Article

U2 - 10.18632/oncotarget.19665

DO - 10.18632/oncotarget.19665

M3 - Article

C2 - 29156718

VL - 8

SP - 85263

EP - 85275

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -